ClinicalTrials.Veeva

Menu

Treatment of Alcohol Withdrawal in Hospital Patients

Virginia Commonwealth University (VCU) logo

Virginia Commonwealth University (VCU)

Status and phase

Completed
Phase 4

Conditions

Alcohol Withdrawal Syndrome

Treatments

Drug: Lorazepam (drug)
Drug: Lorazepam

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00249366
K23AA000222 (U.S. NIH Grant/Contract)
NIAAAWEA-K2300222-A

Details and patient eligibility

About

The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.

Full description

Studies show that symptom-triggered dosing is best for treatment of alcohol withdrawal in patients on chemical dependence units without other illness. On general medical hospital wards, withdrawal may be affected by comorbid medical illness. A clinical trial was undertaken to determine whether there is a difference between symptom-triggered (ST) and fixed-schedule (FS) dosing of lorazepam in patients hospitalized on general medical wards at a University medical center. Subjects were assessed by their nurses with the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale. Subjects in the ST arm received lorazepam doses based on CIWA-Ar score. Subjects in the FS arm received scheduled lorazepam with tapering over 4 days.

Enrollment

183 patients

Sex

All

Ages

21 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Alcohol dependence (based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)
  • Daily alcohol use for at least seven consecutive days with the last use no more than 72 hours prior to enrollment
  • Patients on the General Internal Medicine service

Exclusion criteria

  • Unable to give informed consent
  • Chronically maintained on prescription sedative-hypnotics

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

183 participants in 2 patient groups

Fixed-schedule treatment
Active Comparator group
Description:
Fixed-schedule administration of lorazepam for alcohol withdrawal
Treatment:
Drug: Lorazepam
Drug: Lorazepam (drug)
Symptom-triggered treatment
Active Comparator group
Description:
Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
Treatment:
Drug: Lorazepam
Drug: Lorazepam (drug)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems